Introduction {#Sec1}
============

Retinopathy of prematurity (ROP) is a potentially blinding eye condition, associated with abnormal retinal vascular proliferation at the boundary of vascularised and avascular peripheral retina of prematurely born babies. This can lead to retinal detachment and visual loss \[[@CR1]\]. Regular screening and timely treatment are essential in improving anatomical and functional outcomes and should be part of routine neonatal care. During the 1940/50s and 1970s a first and a second epidemic of ROP blindness affected preterm babies in high-income countries and these were associated with the widespread use of unrestricted oxygen supplementation and increasing survival of infants at lower gestational age (GA) (\<  28 weeks), respectively.

In the 1990s a third epidemic of blindness due to ROP was described, principally in the middle and low income countries of Latin America, Eastern Europe, and later Asia \[[@CR2]\]. In 2010, an estimated 184,700 preterm infants worldwide developed any stage of ROP, and more than 30,000 became visually impaired due to ROP \[[@CR3]\]. In these middle income countries neonatal care is rapidly expanding, leading to greater survival of more immature, small for GA, and low-birth weight infants \[[@CR2], [@CR4]\]. In addition, suboptimal neonatal care, as a result of lack of awareness and resources, can lead to higher rates of severe ROP not only in extremely premature infants but also in larger, more mature infants \[[@CR5], [@CR6]\].

In sub-Saharan Africa, little is known about the incidence of ROP \[[@CR7]--[@CR11]\]. A recent worldwide survey indicated that ROP screening is very limited in Africa \[[@CR12]\]. In Rwanda, major advances in the survival of preterm infants have occurred recently due to improving neonatal care \[[@CR13]\]. As a consequence, more extremely preterm infants are at risk of ROP. The recent presentation of several children born preterm with bilateral inoperable retinal detachment to an Ophthalmology Department in Rwanda prompted us to set up a screening system. A prospective observational study to document the incidence and risk factors for ROP was undertaken in Rwanda's three major neonatal intensive care units (NICU) with level 2 neonatal care (i.e. limited access to ventilation and no total parental nutrition).

Subjects and methods {#Sec2}
====================

A risk factor study was nested within the prospective observational study carried out in the NICUs of three tertiary hospitals in Rwanda from September 2015 to July 2017. Two NICUs were located in the capital city Kigali, i.e. King Faisal Hospital (KFH) and University Teaching Hospital of Kigali (CHUK), and one in Huye, University Teaching Hospital of Huye (University of Rwanda campus Butare, CHUB).The study population were all preterm babies admitted to these NICUs who fulfilled the inclusion criteria, i.e. GA \< 35 weeks or birth weight (BW) \< 1800 grams (g) or an unstable clinical course, as indicated by the paediatrician.

Data management {#Sec3}
---------------

Data on potential risk factors were extracted from daily neonatal progress notes throughout hospital admission on a weekly basis. BW and GA were defined as categorical variables. Exposure to supplemental oxygen was assessed as the number of days in supplemental oxygen (categorical variable) and method of administration, i.e. nasal cannula, continuous positive airway pressure (CPAP) or ventilator \[[@CR10]\]. In cases of nasal cannula, supplemental unblended oxygen was delivered. Initially oxygen saturation was recorded but was felt to be too unreliable as a study variable. Sepsis was defined as early or late (starting 3 or more days after birth), necessitating antibiotic treatment for ≥ 5 days on clinical grounds and/or on the basis of a positive blood culture, if available. Blood transfusion was defined as the administration of adult red blood cells on one or more occasions. Hyperglycaemia was defined as serum glycemia ≥ 150 mg/dl sampled before a meal.

The first eye examination took place 4 weeks after birth. At the beginning of the study six local ophthalmologists were trained in ROP screening by an expert ophthalmologist during joint screening sessions. Quality control on the screening process took place during follow-up visits. Both monocular and binocular indirect ophthalmoscopy were performed using a 20 or 30 dioptre lens and indentation or Missotten--Fabri neonatal lens (Fabrilens, Lommel, Belgium), depending on the preference of the attending ophthalmologist. This lens serves both as a magnifier and speculum to keep the eyelids open. Retinal changes were classified by stage, zones and the presence of plus disease using standard photographs based on the International Classification of ROP and Early Treatment for ROP studies \[[@CR14], [@CR15]\].

The maximum severity of ROP in either eye was the level assigned to each infant. ROP-screening was at least every 2 weeks until vascularisation reached zone III or until 41 weeks postmenstrual age. Weekly screening was scheduled if the vessels ended in zone I or posterior zone II, or if there was any plus disease, or any stage 3 disease in any zone. Treatment-warranted ROP (TW-ROP) was defined Type 1 ROP i.e. ROP in Zone I, stage 3 without plus disease or in Zone I, any stage with plus disease, or ROP in Zone II, Stage 2 and 3 with plus disease \[[@CR15]\].

Statistical analysis {#Sec4}
--------------------

Data were entered into a Microsoft Access database and analysed using STATA-software 9.2 (STATA Corp, College Station, TX). Statistics were presented overall and for the subgroups any ROP, TW-ROP and no ROP. Statistical analysis compared infants with any ROP with those without. Further analysis compared infants with TW-ROP with those without ROP. Potential risk factors were evaluated in univariate logistic regression analyses calculating odds ratios (OR) and 95% confidence intervals (CI) at 0.05 level of significance. Variables which were statistically significant were entered into a multivariate logistic regression model using a backward stepwise method. Assuming a prevalence of any ROP of 15% among exposed and 5% among non-exposed to potential risk factor, a sample size of at least 380 babies was needed to achieve 90% power at the 5% level of significance.

Ethics {#Sec5}
------

The study was conducted in accordance with the Declaration of Helsinki and was approved by the Rwandan National Ethics Committee. An information sheet was read out to parents/caregivers in Kinyarwanda, after which they signed a consent form. All medical eye care related to ROP was provided free of charge. This densely populated country with a reasonably good main infrastructure has a compulsory health insurance system, which facilitates access to health care even for the poor.

Results {#Sec6}
=======

Study population {#Sec7}
----------------

Among 2222 babies admitted to the NICUs, 795 (35.8%) fulfilled the criteria for ROP screening, 424 (53%) of whom were screened. Among the 371 not screened, 270 died before the first screening, 89 were lost to follow-up after discharge and 12 carers refused to participate.

Among the 424 screened, 370 (87.3%) babies completed the screening process, 5 had any ROP documented when they were lost to follow-up, and 49 were still ROP negative when lost to follow-up before vascularisation reached zone III or 41 weeks postmenstrual age. Of those 49 babies 3 died prior to the second eye screening and 28 were seen twice or more.

A total of 31 babies (7.3%, CI 5.0--10.2) developed any ROP, 13 of whom (41.9%, CI 24.5--60.9) required treatment i.e., 3.1% (CI 1.6--5.2) of all babies screened. The demographic and pregnancy characteristics of the premature babies screened are presented in Table [1](#Tab1){ref-type="table"}. There were no sex differences among babies eligible for screening and those screened (*P* = 0.93 and 0.58 respectively). Most babies (*n* = 279) were delivered by Caesarean section (67.7%) and 365 (87.7%) were born in the same hospital as the NICU. The mean age of mothers of babies with ROP tended to be higher than of babies without (mean 31.9 years (SD 6.4, range 18--41) and mean 30.1 years (SD 5.9, range 18--48) respectively) (Table [1](#Tab1){ref-type="table"}).Table 1Demographic and pregnancy characteristics of the premature babies screened for retinopathy of prematurity (*n*  =  424)All infantsNo ROPAny ROPTreatment-warranted ROPMissing data*n*%Missing data*n*%Missing data*n*%Missing data*n*%Primipara913031.3912332.0722.6323.1Received antenatal steroid1126363.71024363.512066.71650.0Positive HIV status mother3961.63561.7200.0200.0Method of delivery1212 Caesarean section27967.726369.01651.6430.8 Forceps/ventouse aided delivery00.000.000.000.0 unaided normal delivery13332.311831.01548.4969.2Sex of the baby77 Male19246.018046.61238.7323.1 Female22554.020653.41961.31076.9No. of gestations88 Singleton30473.128072.72477.4969.2 Twins8520.47820.3722.6430.8 Triplets276.5277.000.000.0Place of birth88 At home20.520.500.000.0 In health centre30.730.800.000.0 In hospital of NICU36587.734188.62477.41184.6 In other hospital4611.13910.1722.6215.4Gestational age (weeks)77 \<2630.720.513.217.7 26 to \<28153.6133.426.500.0 28 to \<304911.8389.81135.5323.1 30 to \<3210625.49725.1929.0538.5 32 to \<3522554.021856.5722.6430.8 ≥35194.6184.713.200.0Birth weight (g)99     \<1000317.5236.0825.8430.8    1000 to \<150019146.017545.61651.6861.5    1500 to \<180011527.710928.4619.417.7    ≥18007818.87720.113.200.0*ROP*  retinopathy of prematurity

The mean GA of those screened was 31.7 weeks (SD 2.2, range 24--37) overall and 30.1 weeks (SD 2.4, range 25--36) in the ROP group. The mean BW was 1479 g (SD 360.1, range 650--2800) overall and 1199 g (SD 303.3, range 685--1800) in the ROP group (Table [1](#Tab1){ref-type="table"}). ROP was seen in six babies with GA \> 30 weeks and BW \> 1500 g (19.4% of ROP-cases), one of whom required treatment (GA 32 weeks with BW 1600 g) (Fig. [1](#Fig1){ref-type="fig"}). The neonatal and clinical data of the babies screened are presented in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. Sepsis occurred in 264 babies (63.6%) overall and in 26 babies (83.9%) in the ROP group. A serum glucose test was available for 151/424 (35.6%) babies, as it was only routinely performed in one NICU. Hyperglycaemia (≥150 mg/dl) was documented in 28 babies (18.5%) overall and in eight babies with ROP (53.3%). Supplemental oxygen was given to 279 babies (67.6%) overall and 27 babies (87.1%) in the ROP group. Blood transfusion was needed in 117 babies (28.1%) overall and 17 babies (54.8%) in the ROP group. Babies not completing the screening process were not significantly different in terms of BW, GA or any other relevant risk factor for ROP. The 89 babies who did not attend for the first screening were similar, except for a significantly lower birth weight (*P* \< 0.001).Fig. 1Distribution of retinopathy of prematurity (ROP) cases by birth weight (BW) and gestational age (GA). The grey area represents BW and GA beyond the American Academy 2013 screening criteria (BW ≤ 1500 g and GA ≤ 30 weeks)Table 2Neonatal and clinical categorical data of the premature babies screened for retinopathy of prematurity (*n*  =  424)All infantsNo ROPAny ROPTreatment-warranted ROPMissing data*n*%Missing data*n*%Missing data*n*%Missing data*n*%Sepsis at some stage99 Based on clinical picture21451.619149.72374.21292.3 Confirmed by positive hemoculture5012.14712.239.717.7 No sepsis15136.414638.0516.100.0Timing of sepsis12841 Early sepsis13352.812253.01150.0541.7 Late sepsis (after 3 postnatal days)11947.210847.01150.0758.3Intraventricular haemorrhage at some stage88 Based on clinical picture51.251.300.000.0 Confirmed by ultrasound71.761.613.217.7 No intraventricular haemorrhage40497.137497.13096.81292.3Necrotising enterocolitis at some stage88 Based on clinical picture337.9297.5412.917.7 Confirmed by X-ray20.520.500.000.0 No necrotising enterocolitis38191.635492.02787.11292.3Patent ductus arteriosus88 Asymptomatic307.2266.8412.9215.4 Hemodynamically significant30.730.800.000.0 No patent ductus arteriosus38392.135692.52787.11184.6Glycemia273257168 Hyperglycaemia at some stage (≥150 mg/dl)2818.52014.7853.3120.0 No documented hyperglycaemia12381.511685.3746.7480.0Total days on any supplemental oxygen1111 None13432.413034.0415.417.7 \<5 days13031.512532.7516.1323.1 5--9 days5613.65213.6412.9323.1 10--24 days5312.84511.8825.8430.8 ≥25 days409.7307.91032.3215.4Received blood transfusion88 None29971.928574.01445.2646.2 Once7518.06216.11341.9753.8 Multiple4210.1389.9412.900.0*ROP*  retinopathy of prematurityTable 3Neonatal and clinical quantitative data of the premature babies screened for retinopathy of prematurity (*n*  =  424)All infantsNo ROPAny ROPTreatment-warranted ROPMissing dataMean (median)± SDMinMaxMissing dataMean (median)± SDMinMaxMissing dataMean (median)± SDMinMaxMissing dataMean (median)± SDMinMaxApgar score 1 min after birth506.68 (7)1.49210456.70 (7)1.521056.54 (7)1.393936.60 (7)1.0758 5 min after birth517.76 (8)1.23310467.76 (8)1.2431057.77 (8)1.035927.82 (8)1.2559 10 min after birth658.39 (9)1.11310588.40 (9)1.1231078.25 (8)1.0361018.1 (8.5)1.169Days of received supplemental oxygen1111 Total days on any supplemental oxygen12.48 (5)17.88113011.02 (5)16.48113026.15 (15)24.1527617.25 (9.5)21.14274 Days on continuous positive airway pressure (CPAP)3.84 (1)6.710473.5 (1)6.240477.07 (5)9.710416.17 (1)8.67023 Days on high flow nasal cannula oxygen7.98 (3)12.750866.53 (3)11.308618.52 (10)19.4207111.08 (5,5)13.79252 Days on a ventilator0.66 (0)4.530580.67 (0)4.750580.56 (0)1.37040 (0)000Average daily weight gain during the first 3 weeks, expressed in g/kg birth weight1702.49 (2.5)0.99151612.50 (2.5)0.991592.36 (2.5)1.051432.2 (2.5)1.1214*ROP*   retinopathy of prematurity

Risk factors for any ROP {#Sec8}
------------------------

Univariate analysis comparing infants with any ROP with those without identified the following risk factors: days in oxygen (OR 2.1, CI 1.5--3.0, *P* \< 0.001), low GA (OR 3.4, CI 1.8--6.4, *P* \< 0.001), low BW (OR 2.3, CI 1.5--3.4, *P* \< 0.001), hyperglycaemia (OR 6.6, CI 2.0--21.5, *P* \< 0.001), blood transfusion (OR 3.5, CI 1.6--7.4, *P* \< 0.001) and sepsis (OR 3.2, CI 1.2--8.6, *P* = 0.01) (Table [4](#Tab4){ref-type="table"}). The APGAR-scores at 1, 5 and 10 min after birth were not significantly associated with ROP. There was evidence of a dose--response effect with increasing prematurity, low birth weight and days in supplemental oxygen (test for trend for each variable, *P* \< 0.001). Oxygen administration using nasal cannula was associated with ROP (*P* \< 0.001) but not administration via CPAP (*P* = 0.63). The onset of sepsis did not significantly affect the incidence of any ROP (*P* = 0.79). In the multivariate logistic regression model, days in oxygen (OR 2.1, CI 1.2--3.6, *P* = 0.01) and hyperglycaemia (OR 3.5, CI 1.0--12.4, *P* = 0.05) were the only factors that remained significant for any ROP. Because BW and GA were highly correlated (*P* \< 0.001), a combined summary variable including both was created, which was of borderline significance in this multivariate model (OR 1.5, CI 1.0--2.2, *P* = 0.06). Days in supplemental oxygen (OR 1.7, CI 1.2--2.6, *P* = 0.007) remained significant but hyperglycaemia did not. No statistically significant interactions between the retained variables were identified, nor was there evidence of a weak fit for the overall models (Pearson chi² test = 3.53, *P* = 0.62 and Pearson chi² test = 11.97, *P* = 0.75, respectively).Table 4Univariate logistic regression analyses of risk factors in relation to development of any retinopathy of prematurity (ROP) versus no ROP among 424 screened premature babies (*n*  =  424)Risk factorsAny ROPOdds ratio95% Confidence interval*P*-valueMaternal age \< 25 years0.980.36--2.720.97Positive HIV status mother0.000.5Received antenatal steroid1.150.52--2.530.72Primipara0.620.26--1.480.28Multiple birth gestation0.780.32--1.860.57Caesarean section0.480.23--1.000.05Birth place outside NICU-hospital2.260.92--5.580.07Male gender0.720.34--1.530.4Prematurity (gestational age in weeks)  Dose--response effect3.411.81--6.41\<0.001  \<285.901.38--25.140.006  28 to \<324.371.84--10.35\<0.001  ≥32BaselineLow birth weight (g)  Dose--response effect2.251.48--3,41\<0.001    \<100026.782.59--277.31\<0.001  1000 to \<15007.040.90--55.230.03  1500 to \<18004.240.49--36.540.15  ≥1800BaselineLow Apgar score 5 min after birth (\<7)0.590.13--2.590.48Sepsis at some stage3.191.19--8.560.01Intraventricular haemorrhage at some stage1.130.14--9.100.91Necrotising enterocolitis at some stage1.690.55--5.160.35Patent ductus arteriosus1.820.59--5.570.29Hyperglycaemia (≥150 mg/dl) at some stage6.632.04--21.50\<0.001Daily weigth gain at 3th week per kg birth weight  12 g \< loss \< 0 g per day1.950.45--8.470.36  0 g ≤ gain \< 5 g per day0.890.20--3.940.88  5 g ≤ gain \< 10 g per day1.420.35--5.700.62  Gain ≥ 10 g per dayBaselineReceived blood transfusion at some stage3.461.63--7.36\<0.001Received supplemental oxygen  Continuous positive airway pressure (CPAP) at some stage0.820.37--1.830.63  Ventilator at some stage5.301.45--19.370.005   Days on high flow nasal cannula oxygen   \<6 daysBaseline   6--16 days0.56--5.130.35  17--86 days5.832.24--15.22\<0.001  Dose--response effect2.871.68--4.91\<0.001Total days on any supplemental oxygen  \<5 daysBaseline  5--9 days1.920.49--7.500.34  10--24 days4.441.35--14.680.007  ≥25 days8.332.48--27.96\<0.001  Dose--response effect2.131.49--3.04\<0.001*ROP*   retinopathy of prematurity

Risk factors for treatment-warranted ROP {#Sec9}
----------------------------------------

Univariate analysis identified the following risk factors for TW-ROP: low BW (OR 5.7, CI 2.3--13.9, *P* \< 0.001), blood transfusion (OR 3.3, CI 1.1--10.2, *P* = 0.03), sepsis (*P* = 0.005) and some categories of low GA (OR 3.5, CI 1.0--11.9, *P* = 0.03) (Table 5 in supplement).

Caesarean section was protective against TW-ROP (OR 0.2, CI 0.06--0.67, *P* = 0.004). Decreasing birth weight was associated with TW-ROP (score test for trend of odds *P* = 0.005). The onset of sepsis did not influence the incidence of TW-ROP (*P* = 0.43). In multivariate analysis the combined variable for BW and GA was an independent risk factor (OR 2.1, CI 1.3--3.6, *P* = 0.002), and Caesarean section remained protective (OR 0.2, CI 0.06--0.71, *P* = 0.01).

Discussion {#Sec10}
==========

Until the late 20th century blindness from ROP was virtually unknown in sub-Saharan Africa, apart from South Africa where ROP accounted for 11% of blindness in children in 1996 \[[@CR5], [@CR16]\]. In 1995 an early Nigerian study found no TW-ROP, but 5.6% had any ROP \[[@CR17]\]. A high proportion of affected babies in this study died \[[@CR17]\]. However, over the last decade NICU services have expanded in sub-Saharan Africa, to help achieve Goal 4 of the U.N. Millennium Development Goals (reduction of under 5-mortality rate) \[[@CR13]\]. Therefore, ROP is expected to have increased, but there are limited recent data on ROP apart from studies in South Africa \[[@CR9], [@CR10], [@CR18], [@CR19]\] and Nigeria \[[@CR11], [@CR20]\].

The proportion of infants screened who developed TW-ROP (3.1%) in our study is similar to that reported from other lower and middle-income settings (1--7.1%) \[[@CR8], [@CR11], [@CR18]\], but the percentage developing any ROP (7.3%) was lower (15-- 47.2%) \[[@CR8], [@CR9], [@CR11], [@CR19], [@CR20]\]. Differences in patient selection, examination methods, and survival rates of premature babies between low and middle-income countries can partly explain this discrepancy \[[@CR5], [@CR9], [@CR20], [@CR21]\], Clinically non-significant ROP stages might also have been underreported in our study because of a learning curve while setting up a screening programme.

Infants with ROP in our study had more days in oxygen, lower BW, lower GA, more episodes of hyperglycaemia and sepsis and needed more blood transfusions than those without, similar to findings in other lower and middle-income country studies \[[@CR9]\].

In our study, oxygen---expressed as the number of days of supplementation---remained a significant risk factor in multivariate analysis. Several studies from middle-income countries failed to identify oxygen exposure as an independent risk factor \[[@CR9], [@CR22], [@CR23]\], while others have shown that improved oxygen delivery and adequate saturation targeting and monitoring in infants receiving oxygen can effectively decrease the incidence of ROP, even in rural areas \[[@CR18], [@CR24]\]. Assessing oxygen exposure reliably requires collecting accurate, continuous data on oxygen saturations---which is difficult to capture. Fluctuation in saturation levels is also important \[[@CR25]\], and in our study settings it was not possible to document oxygen saturations reliably. A recent prospectively planned meta-analysis of individual participant data from extremely preterm infants recruited to large-scale trials to compare different oxygen saturation targets, confirmed that the lower oxygen saturation target (range 85--89%) was associated with a lower risk of ROP treatment compared to the higher range (91--95%), but a higher risk of mortality \[[@CR26]\]. Although oxygen levels are important in the pathogenesis of ROP \[[@CR27]\], finding a balance in oxygen delivery to ensure adequate levels for survival \[[@CR26]\], and at the same time reducing the risk of ROP is not easy. In addition, recommended oxygen saturation levels in extremely low birth weight infants in the postnatal period remain unclear \[[@CR25], [@CR26]\]. We found that CPAP was a safer way of oxygen administration in terms of ROP risk than nasal cannula as has been reported in some, but not all studies \[[@CR9], [@CR28]\]. Differences in the characteristics of the study populations may explain the differences. On the other hand, the administration of CPAP already implicates a closer surveillance of these patients.

In our study only a combined variable of BW and GA remained significant in multivariate analysis and almost one in five babies with any ROP were beyond the 2013 American Academy screening guidelines for BW (≤1500 g) and GA (≤30 weeks) \[[@CR15]\]. The finding that larger and more mature infants are at risk of ROP is in accordance with studies from other middle income countries \[[@CR5]\], suggesting that other modifiable risk factors play an important role in these settings.

In our study two babies with ROP exceeded one of the two study inclusion criteria (\>1800 g BW or \>35 weeks GA), but neither developed TW-ROP. Although screening of ROP can be a cause of stress to preterm infants and is resource intensive \[[@CR19]\], this observation indicates that our wide inclusion criteria should not be narrowed in Rwanda.

Recently the US guidelines have considered slow weight gain as a risk factor \[[@CR29]\]. Due to the lack of total parenteral feeding rapid weight gain rarely occurs in our study setting.

Future local audits analysing screening and treatment data can guide refinements to these screening criteria, if the characteristics of babies with TW-ROP change over time.

As in other studies \[[@CR9], [@CR10], [@CR22]\], sepsis was a significant risk factor for ROP. Perinatal inflammation might play a role in the pathogenesis of ROP due to changing levels of the cytokines involved in angiogenesis \[[@CR30], [@CR31]\]. Although there is some variation depending on the definition of sepsis, rates can be high in NICUs with limited resources. However, even in low-income countries effective low-technology and low-cost nosocomial infection control strategies can be implemented successfully to tackle sepsis \[[@CR9], [@CR32]\].

By prospectively recruiting all consecutive preterm infants born in the three major NICUs, we analysed a representative sample of the prematurely born baby population of tertiary medical centres in Rwanda. However, during the 2-year study neonatal care was introduced in several peripheral district hospitals, and ophthalmology departments witnessed an increasing number of preterm infants admitted for ROP treatment who had received care outside our study centres. Therefore, the incidence of ROP in our study may not reflect the overall incidence. This observation also suggests that the epidemic of ROP has only just begun in Rwanda and that screening needs to be expanded to these peripheral hospitals as well. Remote ROP screening using high-resolution wide-field imaging systems, with interpretation of the images at an off-site reading centre, would be one way to expand coverage, as has been implemented with success in middle and high-income countries with a shortage of eye healthcare professionals \[[@CR33]\]. Recently the application of less expensive systems and even smartphones (iPhone 5 combined with 20D lens) have been described for ROP-screening \[[@CR34]\]. This telemedicine approach might be an option for Rwanda, but care should be taken to train the photographers well, since visualising the peripheral retina, which is of vital importance in ROP screening, can be challenging.

There are some limitations in our study. For example, loss to follow-up, which was in line with other studies from sub-Saharan Africa \[[@CR9]\], may have biased the findings, particularly as those not followed up were born with a lower BW than those who were screened. Although there were no medical costs and transport costs were reimbursed, 17.1% of infants had insufficient screening episodes to ascertain the occurrence of ROP. Difficulties in completing screening following discharge from the NICU have been encountered in other communities \[[@CR35], [@CR36]\]. Further sensitisation of parents and health community on the importance of ROP screening is mandatory to reduce loss to follow-up. Screening before discharge from NICU even if the screening was not yet due, streamlined scheduling, and creation of a log for all patients seen, can improve follow-up after discharge \[[@CR36], [@CR37]\].

Despite offering training and follow-up sessions and the use of standard photographs on ROP-classification, some degree of inter-observer variability and observer bias/measurement error between the study ophthalmologists cannot be ruled out, especially for the clinically milder stages of ROP. Furthermore, assessing the zone of vascularisation is difficult and ceasing screening when vessels have entered zone III might not be safe \[[@CR38]\].

In conclusion, like in other low and middle-income countries, ROP has become an emerging health problem in Rwanda. It is expected that with further economic progress and consequently improved neonatal care, more babies will survive and hence develop ROP in sub-Saharan Africa \[[@CR12]\]. Screening for ROP is indicated beyond the criteria recommended in the 2013 American Academy screening guidelines \[[@CR15]\]. Identification of several potentially modifiable risk factors allows Ministries of Health and other organisations involved in neonatal care and the prevention of blindness in children in sub-Saharan Africa, to direct their efforts to improve neonatal care and establish screening and treatment for ROP.

Summary {#Sec11}
=======

What was known before {#FPar1}
---------------------

ROP is a public health problem in middle-income countries in Asia and Latin America and some countries in South and West Africa.

What this study adds {#FPar2}
--------------------

Although rarely seen a decade before, ROP has now become an important cause of visual impairment in other African countries like Rwanda, requiring programmes for screening and treatment.ROP screening is indicated beyond the 2013 American Academy guidelines in this setting.
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